Adalimumab/etanercept/infliximabDevelopment of autoantibodies: 37 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1537卷 / 1期

关键词：

D O I：

10.1007/s40278-015-7062-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：16 / 16

相关论文

共 50 条

[1] Adalimumab/etanercept/infliximabLupus: 37 case reports
[J]. Reactions Weekly, 2015, 1559 (1) : 17 - 17
[2] Adalimumab/infliximabDevelopment of anti-drug antibodies: 7 case reports
[J]. Reactions Weekly, 2018, 1701 (1) : 15 - 15
[3] Adalimumab/etanercept/infliximabNeuropathy: 12 case reports
[J]. Reactions Weekly, 2016, 1599 (1) : 17 - 17
[4] Adalimumab/etanercept/infliximabPsoriasis: 6 case reports
[J]. Reactions Weekly, 2013, 1438 (1) : 5 - 5
[5] Adalimumab/etanercept/infliximabPsoriasis: 25 case reports
[J]. Reactions Weekly, 2009, 1241 (1) : 6 - 6
[6] Adalimumab/etanercept/infliximabPsoriasis: 4 case reports
[J]. Reactions Weekly, 2008, 1209 (1) : 6 - 6
[7] Adalimumab/etanercept/infliximabTuberculosis: 6 case reports
[J]. Reactions Weekly, 2017, 1672 (1) : 15 - 15
[8] Adalimumab/etanercept/methotrexateSarcoidosis: 3 case reports
[J]. Reactions Weekly, 2012, 1396 (1) : 6 - 6
[9] Adalimumab/etanercept/infliximabMalignancy: 7 case reports
[J]. Reactions Weekly, 2015, 1565 (1) : 19 - 19
[10] Adalimumab/etanercept/infliximabPsoriasis: 2 case reports
[J]. Reactions Weekly, 2016, 1593 (1) : 17 - 17

← 1 2 3 4 5 →